Research Article
The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke
Table 3
Results obtained from comparison of cost-effectiveness of two treatment methods for atrial fibrillation patients.
| | Strategy | Cost (PPP$) | Effectiveness (based on clinical outcomes) | Incremental cost | Incremental effectiveness | ICER (incremental cost per extra success) PPP$ | | Prevention of bleeding | Prevention of ischemic stroke | Prevention of bleeding | Prevention of ischemic stroke |
| | Cost-effectiveness analysis (CEA) | Rivaroxaban | 25275 | 0.82 | 0.99 | 0 | 0 | 0 | Dominant | | Warfarin | 26554 | 0.44 | 0.96 | 1279 | -0.38 | -0.03 | Dominated |
|
|
